Beurs.nl monitor iconMarkt Monitor
  • AEX 0,00 919,26 0,00%
  • DE40 -288,91 22.999,15 -1,24%
  • US500^ 0,00 5.664,36 0,00%
  • US30^ 0,00 41.975,60 0,00%
  • EUR/USD 0,00 1,0829 -0,26%
  • WTI 0,00 68,33 0,00%
  • Gold spot -18,27 3.027,66 -0,60%

Relief therapeutics Holding

9.106 Posts
Pagina: «« 1 ... 67 68 69 70 71 ... 456 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 18 augustus 2020 08:03
    quote:

    Zittenblijvertje schreef op 17 augustus 2020 22:51:

    [...]Nee hoor zoals eerder te lezen viel in een bericht van cash , zijn alle rechten in handen van Relief . En hebben in het recente verleden nog geprobeerd om dit medicijn voor een prikkie te slijten
    NeuroRX voert alle testen uit en vraag merknamen aan, dus het is duidelijk dat NeuroRX wel degelijk bepaalde rechten heeft en dus een flink gedeelte van de evt. opbrengst krijgt.
  2. simidoc 18 augustus 2020 08:23
    quote:

    DeZwarteRidder schreef op 18 augustus 2020 08:03:

    [...]
    NeuroRX voert alle testen uit en vraag merknamen aan, dus het is duidelijk dat NeuroRX wel degelijk bepaalde rechten heeft en dus een flink gedeelte van de evt. opbrengst krijgt.
    Blijven gaan, Zwarte onheilsprofeet.
  3. forum rang 10 DeZwarteRidder 18 augustus 2020 08:37
    Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

    Fishing boat study provides first real-life example of antibodies in action

    17 August 2020 • 7:00pm

    Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

    A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

    “This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

    “This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

    Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

    It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

    However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

    Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

    While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

    However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

    It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

    Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

    These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

    According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

    As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

    www.telegraph.co.uk/global-health/
  4. [verwijderd] 18 augustus 2020 08:50
    quote:

    DeZwarteRidder schreef op 18 augustus 2020 08:37:

    Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

    Fishing boat study provides first real-life example of antibodies in action

    17 August 2020 • 7:00pm

    Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

    A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

    “This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

    “This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

    Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

    It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

    However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

    Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

    While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

    However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

    It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

    Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

    These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

    According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

    As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

    www.telegraph.co.uk/global-health/
  5. [verwijderd] 18 augustus 2020 08:56
    quote:

    Zwartgeld schreef op 18 augustus 2020 08:50:

    [...]
    Jij wakkert zo veel angst in mensen.
    Waneer ze een stukje van jou negatieve analyse proeven men meteen verkoopt .
    Heb al mee gemaakt met wirecard .
    Heb me hoop geld gekost.
    Nu met dit....
  6. thewitte 18 augustus 2020 09:14
    quote:

    Zwartgeld schreef op 18 augustus 2020 08:56:

    [...]Jij wakkert zo veel angst in mensen.
    Waneer ze een stukje van jou negatieve analyse proeven men meteen verkoopt .
    Heb al mee gemaakt met wirecard .
    Heb me hoop geld gekost.
    Nu met dit....

    Quote je nu jezelf? Of val je hier door de mand door met je verkeerde alias te reageren..
  7. forum rang 10 DeZwarteRidder 18 augustus 2020 09:17
    quote:

    Zwartgeld schreef op 18 augustus 2020 08:56:

    [...]Jij wakkert zo veel angst in mensen.
    Waneer ze een stukje van jou negatieve analyse proeven men meteen verkoopt .
    Heb al mee gemaakt met wirecard .
    Heb me hoop geld gekost.
    Nu met dit....
    Je teksten zijn nogal onduidelijk, maar ik wil er nog wel even op wijzen dat ik vorig jaar toen de koers van Wirecard ruim boven de 100 stond, keihard heb gewaarschuwd voor de fraude bij Wirecard.

    Helaas hebben weinig personen zich daar iets van aangetrokken.
  8. forum rang 10 DeZwarteRidder 18 augustus 2020 09:18
    quote:

    thewitte schreef op 18 augustus 2020 09:14:

    [...]Quote je nu jezelf? Of val je hier door de mand door met je verkeerde alias te reageren..
    Zwartgeld zit te knoeien met zwartgeld...........
  9. [verwijderd] 18 augustus 2020 09:18
    quote:

    thewitte schreef op 18 augustus 2020 09:14:

    [...]

    Quote je nu jezelf? Of val je hier door de mand door met je verkeerde alias te reageren..
    Haha mooi hé, valt hij inderdaad even flink door de mand.

  10. [verwijderd] 18 augustus 2020 09:20
    Vanmorgen toch maar 80% verkocht. Ga rustig afwachten of er weer grote partijen verkocht worden waardoor de prijs gedrukt wordt en anders lekker genieten van de gemaakte winst.
  11. forum rang 10 DeZwarteRidder 18 augustus 2020 09:23
    quote:

    NoNoVio schreef op 18 augustus 2020 09:18:

    [...]Haha mooi hé, valt hij inderdaad even flink door de mand.
    Zwartgeld is een newbie, dus wees lief voor hem.....!!
  12. Hangyodon 18 augustus 2020 09:26
    quote:

    Kleintje66 schreef op 18 augustus 2020 09:20:

    Vanmorgen toch maar 80% verkocht. Ga rustig afwachten of er weer grote partijen verkocht worden waardoor de prijs gedrukt wordt en anders lekker genieten van de gemaakte winst.
    hoop ik voor je dat je boven de 50c hebt verkocht en niet onderaan 0.45
9.106 Posts
Pagina: «« 1 ... 67 68 69 70 71 ... 456 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.104
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.047
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.825
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.797
Aedifica 3 925
Aegon 3.258 323.033
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.348
Air France - KLM 1.025 35.260
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.152
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.722
AMG 971 134.211
AMS 3 73
Amsterdam Commodities 305 6.743
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 494
Antonov 22.632 153.605
Aperam 92 15.044
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.931
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.586
ASML 1.766 109.762
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.825
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.442